This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Thousand Oaks, CA-based Amgen is one of the biggest biotech companies in the world, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health and nephrology markets. The company used advances in cellular and molecular biology to develop two of the biotech industry’s earliest and most successful drugs, Epogen (anemia) and Neupogen (white blood cell stimulant). Amgen successfully launched two next-generation products, Aranesp and Neulasta. Meanwhile, the acquisition of Immunex Corporation gave Amgen access to the multi-blockbuster drug, Enbrel. However, all these older drugs are facing declining sales due to biosimilar or branded competition, which is being somewhat offset by its newer blockbuster drugs like Prolia/Xgeva
What's in Store for Merck (MRK) this Earnings Season?
by Zacks Equity Research
Merck & Co., Inc. (MRK) will be reporting first-quarter 2017 earnings on May 2, before market opens. Last quarter, the company delivered a positive earnings surprise of 1.14%.
Pfizer (PFE) Q1 Earnings: Will it Pull Off a Surprise?
by Zacks Equity Research
Pfizer, Inc. (PFE) will report first-quarter 2017 earnings on May 2, before market open. Last quarter, the company delivered a negative earnings surprise of 6.0%.
Gilead (GILD) Q1 Earnings: Stock Likely to Beat Estimates?
by Zacks Equity Research
Gilead Sciences Inc. (GILD) is scheduled to report first-quarter 2017 results on May 2, after the market closes.
Novartis Tops Q1 Earnings: Cosentyx, Entresto Boost Sales
by Zacks Equity Research
Novartis AG (NVS) reported first-quarter 2017 core earnings of $1.13 per share, beating the Zacks Consensus Estimate of $1.10.
Biogen (BIIB) Q1 Earnings & Sales Top, Spinraza Sales Strong
by Zacks Equity Research
Biogen Inc. (BIIB) reported better-than-expected results in the first-quarter of 2017. The company surpassed expectations both for earnings and sales.
Why Earnings Season Could Be Great for Amgen (AMGN)
by Zacks Equity Research
Amgen (AMGN) is seeing encouraging earnings estimate revision activity as of late and carries a favorable rank, positioning the company for a likely beat this season.
Drug Stocks Q1 Earnings Releases on Apr 26: AMGN, GSK & More
by Zacks Equity Research
Here we have four pharma companies that are set to report first-quarter results on Apr 26. Let's see how things are shaping up for this quarter.
Celgene (CELG) to Post Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Celgene Corporation (CELG) is scheduled to report first-quarter 2017 results on Apr 27, before the opening bell.
What's in Store for Agenus (AGEN) this Earnings Season?
by Zacks Equity Research
Agenus Inc. (AGEN) is expected to report first-quarter 2017 results later this month or early next month.
Amgen (AMGN) to Report Q1 Earnings: Will it Beat Again?
by Zacks Equity Research
We expect biotech major Amgen Inc. (AMGN) to beat expectations when it reports first-quarter 2017 results on Apr 26 after the market closes.
Alexion (ALXN) Q1 Earnings: Can the Stock Pull a Surprise?
by Zacks Equity Research
Alexion Pharmaceuticals, Inc. (ALXN) is scheduled to report first quarter 2017 results on Apr 27, before the opening bell.
Universal Health (UHS) Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Universal Health Services, Inc (UHS) is set to report first-quarter 2017 results on Apr 25, after the market closes.
Eli Lilly (LLY) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Eli Lilly and Company (LLY) will report first-quarter 2017 results on Apr 25, before the market opens.
Novartis (NVS) Q1 Earnings: Will the Stock Disappoint?
by Zacks Equity Research
Swiss pharmaceutical company Novartis AG (NVS) is scheduled to report first-quarter 2017 results on Apr 25.
What's in Store for Biogen (BIIB) this Earnings Season?
by Zacks Equity Research
Biogen Inc. (BIIB), a well-known name in the multiple sclerosis (MS) market, will report first-quarter 2017 results on Apr 25, before the market opens.
What's in the Cards for Centene (CNC) this Earnings Season?
by Zacks Equity Research
Centene Corporation (CNC)will release first-quarter 2017 results on Apr 25, before the market opens.
by Zacks Equity Research
5 Major Drug Stocks Likely to Beat Q1 Earnings Estimates
by Zacks Equity Research
2017 is expected to be a strong year for drug stocks.
Top Research Reports for Alphabet, Amgen & Lowe's
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Alphabet (GOOGL), Amgen (AMGN), and Lowe's (LOW).
Mylan Down on FDA Warning Letter to Manufacturing Facility
by Zacks Equity Research
Shares of Mylan, Inc. (MYL) dropped 2% after the company received a warning letter from the FDA for its manufacturing facility in India
ANTH's (ANTH) Blisibimod Completes Dosing in Phase III Study
by Zacks Equity Research
Anthera Pharmaceuticals, Inc. (ANTH) recently announced the completion of dosing in a phase II study, BRIGHT-SC. The study evaluated key pipeline candidate blisibimod for treatment of patients with IgA nephropathy (IgAN).
Amgen Files for Xgeva Label Expansion, To Include Myeloma
by Zacks Equity Research
Amgen, Inc. (AMGN) recently announced that it has submitted a supplemental Biologics License Application (sBLA) to the FDA to expand the label of its key drug, Xgeva.
Biotech Stock Roundup: Acorda Down on Court Ruling, Patent Challenge for CELG Drug
by Arpita Dutt
Court rulings and patent challenges made headlines in the biotech sector with companies like Acorda (ACOR) and Celgene (CELG) providing updates.
Why Is Amgen (AMGN) Up 12.9% Since the Last Earnings Report?
by Zacks Equity Research
Amgen (AMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Kite Pharma Completes Filing for CAR-T Therapy with FDA
by Zacks Equity Research
Kite Pharma, Inc. (KITE) announced that it has completed the filing of a rolling submission of the Biologics License Application (BLA) for its lead pipeline candidate, axicabtagene ciloleucel to the FDA.